We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+11.49%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.41B
AUM Growth
+$352M
Cap. Flow
+$81.2M
Cap. Flow %
1.5%
Top 10 Hldgs %
72.74%
Holding
42
New
2
Increased
11
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$55.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$54.5M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$32.8M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$24.2M
5
KYMR icon
Kymera Therapeutics
KYMR
+$24M

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$66.8M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$48.6M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$21.7M
4
KURA icon
Kura Oncology
KURA
+$19.7M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$692M 12.78%
10,125,000
+320,000
+3% +$18.9M
UTHR icon
2
United Therapeutics
UTHR
$26.1B
$613M 11.32%
2,926,500
-43,500
-1% -$9.73M
ARGX icon
3
argenx
ARGX
$55.2B
$447M 8.25%
1,265,555
– –
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$388M 7.16%
5,550,555
– –
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.64B
$351M 6.48%
3,175,000
-215,000
-6% -$21.7M
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$317M 5.86%
5,125,000
+125,000
+3% +$8.73M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$11.9B
$301M 5.57%
3,555,555
+271,555
+8% +$24.2M
ASND icon
8
Ascendis Pharma A/S
ASND
$16.5B
$294M 5.44%
2,850,000
+575,000
+25% +$54.5M
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$280M 5.17%
26,800,000
– –
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
$255M 4.71%
1,865,000
+340,000
+22% +$55.4M
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$38.3B
$221M 4.09%
1,105,000
-255,000
-19% -$48.6M
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.1B
$177M 3.27%
4,900,000
– –
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.42B
$114M 2.11%
9,050,000
+2,550,000
+39% +$32.8M
ISEE
14
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$106M 1.96%
5,900,000
-1,220,000
-17% -$16M
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$12.6B
$99.8M 1.84%
1,535,000
– –
KRYS icon
16
Krystal Biotech
KRYS
$10.7B
$88.9M 1.64%
1,275,000
+200,000
+19% +$14.4M
IOVA icon
17
Iovance Biotherapeutics
IOVA
$2.04B
$86.4M 1.6%
9,020,000
-200,000
-2% -$2.31M
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.7B
$53.4M 0.99%
2,222,222
– –
MRSN
19
DELISTED
Mersana Therapeutics
MRSN
$51M 0.94%
302,000
– –
KURA icon
20
Kura Oncology
KURA
$793M
$48.2M 0.89%
3,525,000
-1,275,000
-27% -$19.7M
KYMR icon
21
Kymera Therapeutics
KYMR
$8.66B
$47.2M 0.87%
2,169,230
+909,230
+72% +$24M
WHWK
22
Whitehawk Therapeutics
WHWK
$181M
$40.3M 0.74%
2,849,402
+1,020,000
+56% +$13.4M
DSGN icon
23
Design Therapeutics
DSGN
$751M
$37.2M 0.69%
2,222,222
– –
PMVP icon
24
PMV Pharmaceuticals
PMVP
$57.1M
$36.4M 0.67%
3,060,000
-40,000
-1% -$578K
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
$36M 0.67%
10,300,000
– –
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Avoro Capital Advisors held 42 positions worth $5.41B, up 7% from $5.06B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Avoro Capital Advisors's Q3 2022 filing shows 2 new, 11 increased, 7 reduced and 3 closed positions. Its largest new stake was Amylyx Pharmaceuticals: 650,000 shares worth $18.3M. The largest sale was State Street SPDR S&P Biotech ETF, an estimated $66.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

  • Avoro Capital Advisors's largest Q3 2022 buy was Amylyx Pharmaceuticals: 650,000 shares worth $18.3M.
  • Avoro Capital Advisors added most to Seagen Inc. Common Stock in Q3 2022, an estimated $55.4M increase.
  • Avoro Capital Advisors's biggest Q3 2022 reduction was Alnylam Pharmaceuticals, cutting an estimated $48.6M.
  • Avoro Capital Advisors fully exited State Street SPDR S&P Biotech ETF in Q3 2022, selling an estimated $66.8M.
  • Avoro Capital Advisors's ten largest holdings make up 73% of its $5.41B portfolio in Q3 2022.
  • Avoro Capital Advisors opened 2 new positions and closed 3 in Q3 2022.
  • Avoro Capital Advisors's portfolio value rose 7% quarter-over-quarter to $5.41B.

Based on Avoro Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.